Potential antidepressant activity of sigma ligands

Polish Journal of Pharmacology

Volumn 55, Issue 6, 2003, Pages 923-934

  Skuza, Grazyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Animal models; Antidepressant activity; Selective sigma ligands; Sigma receptors

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; AMANTADINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CYCLIC GMP; DESIPRAMINE; DOPAMINE; FLUOXETINE; GLUTAMIC ACID; IGMESINE; IMIPRAMINE; MEMANTINE; MILNACIPRAN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; NORADRENALIN; PAROXETINE; PRAMIPEXOLE; REBOXETINE; RECEPTOR SUBTYPE; SEROTONIN; SIGMA 1 OPIATE RECEPTOR; SIGMA OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; UNINDEXED DRUG; VENLAFAXINE;

BINDING SITE; BRAIN REGION; DEPRESSION; DISEASE MODEL; DOPAMINERGIC SYSTEM; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; RECEPTOR AFFINITY; RECEPTOR BINDING; REVIEW; SEROTONINERGIC SYSTEM;

ANIMALS; ANTIDEPRESSIVE AGENTS; CINNAMATES; CYCLOPROPANES; HUMANS; LIGANDS; PIPERAZINES; QUINOLONES; RECEPTORS, SIGMA;

EID: 1642462292     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Akunne H.C., Zoski K.T., Whetzel S.Z., Cordon J.J., Brandon R.M., Roman F., Pugsley T.A.: Neuropharmacological profile of a selective sigma ligand, igmesine: a potential antidepressant. Neuropharmacology, 2001, 41, 138-149.
2. Bergeron R., Debonnel G., de Montigny C.: Modification of the NMDA response by antidepressant σ-receptor ligands. Eur. J. Pharmacol., 1993, 240, 319-323.
3. Bergeron R., de Montigny C., Debonnel G.: Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via σ receptors. J. Neurosci., 1996, 16, 1193-1202.
4. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H.: Antidepressant effects of ketamine in depressed patients. Biol. Psychiat., 2000, 47, 351-354.
5. 2 receptor subtypes. Neuroscience, 1997, 76, 467-477.
6. Borsini F., Meli A.: Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology, 1988, 94, 147-160.
7. Brent P.J., Herd L., Saunders H., Sim A.T.R., Dunkley P.R.: Protein phosphorylation and calcium uptake into rat forebrain synaptosomes: modulation by the σ-ligand, 1,3-ditolylguanidine. J. Neurochem., 1997, 68, 2201-2211.
8. Bunney W.E., Davis J.M.: Norepinephrine in depressive reactions. Arch. Gen. Psychiat., 1965, 13, 483-494.
9. Christensen A.V., Fjalland B., Pedersen V., Danneskiold-Samsoe P., Svendsen O.: Pharmacology of the new phthalane (Lu 10-171), with specific 5-HT uptake inhibiting properties. Eur. J. Pharmacol., 1977, 41, 153-162.
10. 1 ligand, igmesine, on neurotransmitter activity in the rat as assessed by intracerebral microdialysis. Soc. Neurosci. Abstr., 1998, 24, Part 2, 583, 14.
11. Coppen A.J.: Biochemical aspects of depression. Int. Psychiat. Clin., 1969, 6, 53-81.
12. 2 ligands. Synapse, 1998, 29, 62-71.
13. Debonnel G., de Montigny C.: Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci., 1996, 58, 721-734.
14. Derbez A.E., Mody R.M., Werling L.L.: Sigma(2)-receptor regulation of dopamine transporter via activation of protein kinase C. J. Pharmacol. Exp. Ther., 2002, 301, 306-314.
15. 1A receptor antagonists. Psychopharmacology, 1995, 119, 47-54.
16. Dziedzicka-Wasylewska M., Rogoz R., Klimek V., Maj J.: Repeated treatment of antidepressant drugs affects the levels of mRNA coding for D-1 and D-2 dopamine receptors in the rat brain. J. Neural Transm., 1997, 104, 515-524.
17. 3 receptors. Behav. Pharmacol., 2002, 13, 127-138.
18. Earley B., Canney M., Clune B., Caldwell M., Leonard B.E., Junien J.-L.: The effects of MK-801, ifenprodil, JO 1784, JO 1994 and JO 1997 on PK 11195 receptor binding, nitric oxide synthase (NO synthase) activity and infarct volume in a mouse model of focal cerebral ischaemia. Neurochem. Int., 1996, 28, 509-521.
19. Ferris C.D., Hirsh D.J., Brooks B.P., Snyder S.H.: Sigma receptors: from molecule to man. J. Neurochem., 1991, 57, 729-737.
20. Fuller R.W., Perry K.W., Molloy B.B.: Effect of an uptake inhibitor on serotonin metabolism in rat brain: studies with 3-(p-tri-fluoromethylphenoxy)-N-methyl-3-phenylpropylamine (Lilly 110140). Life Sci., 1974, 15, 1161-1171.
21. Gronier B., Debonnel G.: Involvement of σ receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems. Eur. J. Pharmacol., 1999, 368, 183-196.
22. Gudelsky G.A.: Effects of σ receptor ligands on extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat. Eur. J. Pharmacol., 1995, 286, 223-228.
23. Gundlach A.L., Largent B.L., Snyder S.H.: Phencyclidine and sigma opiate receptors in brain: biochemical and authoradiographical differentiation. Eur. J. Pharmacol., 1985, 113, 465-466.
24. 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol., 1994, 268, 9-18.
25. Huber M.T., Gotthardt U., Schreiber W., Krieg J.C.: Efficacy of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial. Pharmacopsychiatry, 1999, 32, 68-72.
26. Itzhak Y.: Multiple affinity binding states of the σ receptor: effect of GTP-binding protein-modifying agents. Mol. Pharmacol., 1989, 36, 512-517.
27. Itzhak Y., Kassim C.O.: Clorgyline displays high affinity for σ sites in C57-BL/6 mouse brain. Eur. J. Pharmacol., 1990, 176, 107-108.
28. Ivory J.D.: The effects of putative antipsychotic drugs and antidepressants on σ-receptors in the rat brain. M.Sc. Thesis, National University of Ireland, 1994.
29. 1A receptors. Soc. Neurosci. Abstr., 2000, 26, 1043.
30. 1 Receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain. Neurochem. Res., 1997, 22, 1105-1109.
31. Koe B.K., Weissman A., Welch W.M., Browne R.G.: Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J. Pharmacol. Exp. Ther., 1983, 226, 686-700.
32. Kornhuber J., Schoppmeyer K., Riderer P.: Affinity of 1-aminoadamantanes for the sigma binding site in postmortem human frontal cortex. Neurosci. Lett., 1993, 163, 129-131.
33. Largent B.L., Wikstrom H., Gundlach A.L., Snyder S.H.: Structural determinants of σ-receptor affinity. Mol. Pharmacol., 1987, 32, 772-794.
34. 2 binding in rat brain. Eur. J. Pharmacol., 1994, 259, 65-69.
35. Leonard B.E.: The potential contribution of sigma receptors to antidepressant actions. In: Antidepressants: New Pharmacological Strategies. Ed. Skolnick P., Humana Press, Totowa, 1997, 159-172.
36. Leonard B.E., Nicholson C.D.: σ-Ligands as potential psychotropic drugs. J. Psychopharmacol., 1994, 8, 64-65.
37. Maj J.: Repeated treatment with antidepressant drugs: responses mediated by brain dopamine receptors. In: New Results in Depression Research. Eds. Hippius H., Klerman G.L., Matussek N., Springer-Verlag, Berlin, Heidelberg, 1986, 90-98.
38. Maj J.: Pharmacology of antidepressant drugs. In: Neuropharmacology - Today and Tomorrow (Polish). Eds.: Bijak M., Lasoń W., Platan, Kraków, 2000, 71-100.
39. 3 receptors in the rat brain. Eur. J. Pharmacol., 1998, 351, 31-37.
40. 2 receptors in the rat brain. Eur. J. Pharmacol., 1996, 304, 49-54.
41. Maj J., Mogilnicka E., Klimek V., Kordecka-Magiera A.: Chronic treatment with antidepressant: potentiation of clonidine-induced aggressiveness in mice via noradrenergic mechanism. J. Neural Transm., 1981, 52, 189-197.
42. Maj J., Przegaliński E., Mogilnicka E.: Hypotheses concerning the mechanism of action of antidepressant drugs. Rev. Physiol. Biochem. Pharmacol., 1984, 100, 1-74.
43. Maj J., Rog-acoz Z., Skuza G., Kołodziejczyk K.: Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J. Neural Transm., 1997, 104, 525-533.
44. Maj J., Rogóz Z., Skuza G., Sowińska H.: The effects of repeated treatment with antidepressant drugs on the action of D-amphetamine and apomorphine in rats. In: Neuropharmacology 85'. Eds. Keleman K., Magyar K., Vizi E.S., Académiai Kiadó, Budapest, 1985, 133-139.
45. 2 agonist. J. Neural Transm.-Gen. Sect., 1989, 78, 1-8.
46. Maj J., Rogóz Z., Skuza G., Sowińka H.: Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. Eur. Neuropsychopharmacol., 1992, 2, 37-41.
47. Maj J., Rogóz Z., Skuza G., Sowińska H.: The effects of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in the forced swimming test. Pol. J. Pharmacol., 1992, 44, 337-346.
48. Manallack D.T., Beart P.M., Gundlach A.M.: Psychotomimetic σ-opiates and PCP. Trends Pharmacol. Sci., 1986, 7, 448-451.
49. Martin W.R., Eades C.G., Thompson J.A., Huppler E., Gilbert P.E.: The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther., 1976, 197, 517-532.
50. 1 Receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur. J. Pharmacol., 1996, 312, 267-271.
51. 1 receptor agonist. Eur. J. Pharmacol., 1996, 306, 271-279.
52. Maurice T., Hiramatsu M., Itoh J., Kameyama T., Hasegawa T., Nabeshima T.: Behavioral evidence for a modulating role of σ ligands in memory processes. I. Attenuation of dizocilpine (MK-801 -induced amnesia. Brain Res., 1994, 647, 44-56.
53. 1) receptor: pharmacological evidence and therapeutic opportunities. Jpn. J. Pharmacol., 1999, 81, 125-155.
54. 1 receptor agonist properties, facilitates NMDA receptor-dependent learning in mice. Eur. J. Pharmacol., 1997, 328, 9-18.
55. 3H]SKF-10,047 binding sites (σ sites) exhibit an unique distribution in rat brain subcellular fractions. Eur. J. Pharmacol., 1990, 188, 211-218.
56. McCann D.J., Weissman A.D., Su T.-P.: Sigma-1 and sigma-2 sites in rat brain: comparison of regional, ontogenetic, and subcellular patterns. Synapse, 1994, 17, 182-189.
57. 1 receptor agonist SA4503 significantly alters the activity of midbrain dopamine neurons in rats: in vivo electrophysiological studies. Synapse, 1999, 33, 129-140.
58. 1-binding site by photoaffinity labeling and ligand-directed antibodies. Mol. Pharmacol., 1993, 44, 966-971.
59. Monnet F.P. Debonnel G., Junien J.-L., de Montigny C.: N-methyl-D-aspartate-induced neuronal activation is selectively modulated by σ receptors. Eur. J. Pharmacol., 1990, 179, 441-445.
60. 1 receptor modulates phospholipase C and protein kinase C activities in the brainstem. Proc. Nat. Acad. Sci. USA, 1999, 96, 8196-8199.
61. Okuyama S., Imagawa Y., Ogawa S., Araki H., Ajima A., Tanaka M., Muramatsu M., Nakazato A., Yamaguchi K., Yoshida M.: NE-100, a novel sigma receptor ligand: in vivo tests. Life Sci., 1993, 43, PL285-290.
62. Papp M., Moryl E.: Similar effects of chronic treatment with imipramine and the NMDA antagonists CGP 37849 and MK-801 in a chronic mild stress model of depression. Eur. Neuropsychopharmacol., 1993, 3, 348-349.
63. Papp M., Moryl E.: Antidepressant activity of noncompetitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur. J. Pharmacol., 1996, 263, 1-7.
64. Paul I.A., Nowak G., Layer R.T., Popik P., Skolnick P.: Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J. Pharmacol. Exp. Ther., 1994, 269, 95-102.
65. Quirion R., Bowen W.D., Itzhak Y., Junien J.M., Mussacchio J.M., Rothman T.P., Su T.P., Tam S.W., Taylor D.P.: A proposal on the classification of sigma binding sites. Trends Pharmacol. Sci., 1992, 13, 85-86.
66. Quirion R., Chicheportiche R., Contreras P.C., Johnson K.M., Lodge D., Tam S.W., Woods J.H., Zukin S.R.: Classification and nomenclature of phencyclidine and sigma receptor sites. Trends Pharmacol. Sci., 1987, 10, 444-446.
67. Randrup A., Munkvad I., Fog R., Gerlach J., Molander R., Kjellenberg B., Scheel-Krüger J.: Mania, depression and brain dopamine. Curr. Dev. Psychopharmacol., 1975, 2, 207-229.
68. Rao T.S., Mick S.J., Cler J.A., Emmet M.R., Dilworth V.M., Contreras P.C., Gray N.M., Wood P.L., Iyengar S.: Effects of sigma ligands on mouse cerebellar cyclic guanosine monophosphate (cGMP) levels in vivo: further evidence for a functional modulation of N-methyl-D-aspartate (NMDA) receptor complex-mediated events by sigma ligands. Brain Res., 1991, 561, 43-50.
69. 3 receptors in the rat brain differentiated by agonist and antagonist binding - an authoradiographic analysis. Naunyn-Schmied. Arch. Pharmacol., 1999, 359, 178-186.
70. Rogóz Z., Skuza G., Maj J., Danysz W.: Synergistic effects of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology, 2002, 42, 1024-1030.
71. 2 ligand Lu 28-179 has potent anxiolytic-like effects in rodents. J. Pharmacol. Exp. Ther., 1997, 283, 1323-1332.
72. Sánchez C., Meier E.: Behavioural profile of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology, 1997, 129, 197-205.
73. 2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. Behav. Pharmacol., 2000, 11, 117-124.
74. 1 receptor ligand and potential atypical antipsychotic, on A9 and A10 dopamine neurons. Eur. J. Pharmacol., 1999, 378, 31-37.
75. Schildkraut J.J.: The catecholamine hypothesis of affective disorders: a review of supporting evidence. Amer. J. Psychiat., 1965, 122, 509-522.
76. 1 receptor agonist, on memory impairments induced by cholinergic dysfunction in rats. Eur. J. Pharmacol., 1996, 315, 1-10.
77. Seth P., Fei Y.J., Li H.W., Huang W., Leibach F.H., Ganapathy V.: Cloning and functional characterization of a sigma receptor from rat brain. J. Neurochem., 1998, 70, 22-31.
78. Shirayama Y., Nishikawa T., Umino A., Takahasi K.: p-Chlorophenylalanine-reversible reduction of sigma binding sites by chronic imipramine treatment in rat brain. Eur. J. Pharmacol., 1993, 237, 117-126.
79. Skolnick P.: Antidepressants for the new millennium. Eur. J. Pharmacol., 1999, 375, 31-40.
80. Skolnick P., Layer R.T., Popik P., Nowak G., Paul I.A., Trullas R.: Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry, 1996, 29, 23-26.
81. Skuza G., Góralska M., Dziedzicka-Wasylewska M.: Effects of repeated administration of SA4503, a selective receptor agonist, on dopamine receptors in rat brain. Eur. Neuropsychopharmacol., 2001, 11, Suppl. 2, S44.
82. 1-adrenergic system. A behavioral study. Pol. J. Pharmacol., 2001, 53, 547-550.
83. Skuza G., Rogóz Z.: Effect of 1,3-di-o-tolylguanidine (DTG), rimcazole and EMD 57445, the σ receptor ligands, in the forced swimming test. Pol. J. Pharmacol., 1997, 49, 329-335.
84. 1 receptor agonist. Behav. Pharmacol., 2002, 13, 537-543.
85. Skuza G., Rogóz Z.: Effect of combined treatment with selective σ ligands and amantadine in the forced swimming test in rats. Pol. J. Pharmacol., 2002, 54, 699-702.
86. 3H]Lu 28-179. Neurosci. Abstr., 1997, 2, 1496.
87. Sulser F., Vetulani J., Mobley P.L.: Mode of action of antidepressant drugs. Biochem. Pharmacol., 1978, 27, 257-261.
88. 1A receptor agonist OPC-14523. Neuropharmacology, 2001, 41, 976-988.
89. Trullas R., Skolnick P.: Functional antagonists of the NMDA receptor complex exhibit antidepressant action. Eur. J. Pharmacol., 1990, 185, 1-10.
90. Ukai M., Maeda H., Nanya Y., Kameyama T., Matsuno K.: Beneficial effects of acute and repeated administrations of σ receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol. Biochem. Behav., 1998, 61, 247-253.
91. 1 receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J. Pharmacol. Exp. Ther., 2001, 298, 1269-1279.
92. Vetulani J., Nalepa I.: Antidepressants: past, present and future. Eur. J. Pharmacol., 2000, 405, 351-363.
93. Vetulani J., Sulser F.: Action of various antidepressant treatment reduces reactivity of noradrenergic cyclic AMP generating system in limbic forebrain. Nature, 1975, 257, 495-496.
94. Walker J.M., Bowen W.D., Walker F.O., Matsumoto R.R., De Costa B., Rice K.C.: Sigma receptors: biology and function. Pharmacol. Rev., 1990, 42, 355-402.
95. Willner P.: The mesolimbic dopamine system as a target for rapid antidepressant action. Int. Clin. Psychopharmacol., 1997, 12, Suppl. 3, S7-S14.
96. Wood P.L.: Pharmacology of the second messenger, cyclic guanosine 3′,5′-monophosphate, in the cerebellum. Pharmacol. Rev., 1991, 43, 1-25.
97. Yamamoto H., Yamamoto Y., Sagi N., Klenerova V., Goji K.: σ Ligands indirectly modulate the NMDA receptor ion channels complex on intact neuronal cells via σ-1 sites. J. Neurosci., 1995, 15, 731-736.
98. Zou L.-B., Yamada K., Nabeshima T.: σ Receptor ligands (+)-SKF10,047 and SA4503 improve dizocilpine-induced spatial memory deficits in rats. Eur. J. Pharmacol., 1998, 355, 1-10.